Accelerating the Development of Biologic Therapeutics through Advanced Analytics
BioAnalytix is developing and applying advanced analytic methods and data to enable, improve and accelerate biologic therapeutics from development through market
What We Do
BioAnalytix is a pharmaceutically oriented spin-out from the Barnett Institute of Chemical and Biological Analysis at Northeastern University. Founded in 2012 by thought leaders in biologic drug development, regulatory strategy, and advanced analytics, BioAnalytix works with leading pharmaceutical companies to develop and apply advanced analytic technologies, methods and data in enabling, improving and accelerating biologic therapeutics from development through market.
Mapping Critical Quality Attributes of a Biopharmaceutical In Vivo by Unique Affinity Purification and Advanced LC-MS Methods
Washington, DC – (January 27, 2016) – BioAnalytix announces poster presentation of advanced In Vivo CQA Mapping approaches in biopharmaceutical development. Full Abstract »
Thermo Fisher Scientific and BioAnalytix Collaborate To Develop Advanced Biopharmaceutical Analysis Workflows
San Jose, Calif. – (June 11, 2014) – Scientists at Thermo Fisher Scientific and BioAnalytix, Inc., of Cambridge, MA, are combining their expertise to develop advanced analytical profiling platforms and applications to characterize biologic and biosimilar drugs. Full Press Release »